Cargando…

The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer

The L10P single nucleotide polymorphism (SNP) is located in the signal sequence of the transforming growth factor β1 (TGFβ1) gene. The proline-encoding (Pro-) allele of this SNP has been associated with an increased breast cancer risk, which has been attributed to the elevated secretion of this TGFβ...

Descripción completa

Detalles Bibliográficos
Autores principales: Taubenschuß, Eva, Marton, Erika, Mogg, Maurice, Frech, Barbara, Ehart, Lisa, Muin, Dana, Schreiber, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759865/
https://www.ncbi.nlm.nih.gov/pubmed/23887657
http://dx.doi.org/10.3390/ijms140815376
_version_ 1782282697846030336
author Taubenschuß, Eva
Marton, Erika
Mogg, Maurice
Frech, Barbara
Ehart, Lisa
Muin, Dana
Schreiber, Martin
author_facet Taubenschuß, Eva
Marton, Erika
Mogg, Maurice
Frech, Barbara
Ehart, Lisa
Muin, Dana
Schreiber, Martin
author_sort Taubenschuß, Eva
collection PubMed
description The L10P single nucleotide polymorphism (SNP) is located in the signal sequence of the transforming growth factor β1 (TGFβ1) gene. The proline-encoding (Pro-) allele of this SNP has been associated with an increased breast cancer risk, which has been attributed to the elevated secretion of this TGFβ1 variant observed in vitro and in male subjects. Here we investigated the association of the L10P SNP with serum levels of TGFβ1 in female breast cancer patients and controls. We genotyped the L10P SNP in 276 breast cancer patients and 255 controls. Serum TGFβ1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in a subset of the study population (n = 211). We found no evidence for an association of the L10P SNP with breast cancer risk (per-allele odds ratio: 0.91; 95% confidence interval: 0.71–1.16). However, patients with the Pro/Pro genotype exhibited a significantly younger age at breast cancer onset (55.2 ± 14.3 years) than Leu/Leu patients (60.6 ± 13.6 years; p = 0.04), which may reflect the ability of TGFβ to promote tumor progression. Mean TGFβ1 serum levels of Pro-allele carriers were 39.4 ± 7.4 ng/mL, whereas those of Leu/Leu subjects were 37.6 ± 6.0 ng/mL (p = 0.07). Thus, compared to a previous study of male subjects, we observed only a modest increase, if any, in TGFβ1 levels of female Pro-allele carriers.
format Online
Article
Text
id pubmed-3759865
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37598652013-09-03 The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer Taubenschuß, Eva Marton, Erika Mogg, Maurice Frech, Barbara Ehart, Lisa Muin, Dana Schreiber, Martin Int J Mol Sci Article The L10P single nucleotide polymorphism (SNP) is located in the signal sequence of the transforming growth factor β1 (TGFβ1) gene. The proline-encoding (Pro-) allele of this SNP has been associated with an increased breast cancer risk, which has been attributed to the elevated secretion of this TGFβ1 variant observed in vitro and in male subjects. Here we investigated the association of the L10P SNP with serum levels of TGFβ1 in female breast cancer patients and controls. We genotyped the L10P SNP in 276 breast cancer patients and 255 controls. Serum TGFβ1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in a subset of the study population (n = 211). We found no evidence for an association of the L10P SNP with breast cancer risk (per-allele odds ratio: 0.91; 95% confidence interval: 0.71–1.16). However, patients with the Pro/Pro genotype exhibited a significantly younger age at breast cancer onset (55.2 ± 14.3 years) than Leu/Leu patients (60.6 ± 13.6 years; p = 0.04), which may reflect the ability of TGFβ to promote tumor progression. Mean TGFβ1 serum levels of Pro-allele carriers were 39.4 ± 7.4 ng/mL, whereas those of Leu/Leu subjects were 37.6 ± 6.0 ng/mL (p = 0.07). Thus, compared to a previous study of male subjects, we observed only a modest increase, if any, in TGFβ1 levels of female Pro-allele carriers. Molecular Diversity Preservation International (MDPI) 2013-07-24 /pmc/articles/PMC3759865/ /pubmed/23887657 http://dx.doi.org/10.3390/ijms140815376 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Taubenschuß, Eva
Marton, Erika
Mogg, Maurice
Frech, Barbara
Ehart, Lisa
Muin, Dana
Schreiber, Martin
The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
title The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
title_full The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
title_fullStr The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
title_full_unstemmed The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
title_short The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
title_sort l10p polymorphism and serum levels of transforming growth factor β1 in human breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759865/
https://www.ncbi.nlm.nih.gov/pubmed/23887657
http://dx.doi.org/10.3390/ijms140815376
work_keys_str_mv AT taubenschußeva thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT martonerika thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT moggmaurice thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT frechbarbara thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT ehartlisa thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT muindana thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT schreibermartin thel10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT taubenschußeva l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT martonerika l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT moggmaurice l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT frechbarbara l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT ehartlisa l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT muindana l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer
AT schreibermartin l10ppolymorphismandserumlevelsoftransforminggrowthfactorb1inhumanbreastcancer